302 related articles for article (PubMed ID: 25636086)
21. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
[TBL] [Abstract][Full Text] [Related]
23. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML
Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713
[TBL] [Abstract][Full Text] [Related]
24. TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection.
Chen YL; Jeng YM; Chang CN; Lee HJ; Hsu HC; Lai PL; Yuan RH
Int J Surg; 2014; 12(7):659-65. PubMed ID: 24866078
[TBL] [Abstract][Full Text] [Related]
25. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
[TBL] [Abstract][Full Text] [Related]
26. Genetics: genetics of biliary tract cancer.
Ray K
Nat Rev Gastroenterol Hepatol; 2013 Dec; 10(12):692. PubMed ID: 24247265
[No Abstract] [Full Text] [Related]
27. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators.
Fujimoto A; Totoki Y; Abe T; Boroevich KA; Hosoda F; Nguyen HH; Aoki M; Hosono N; Kubo M; Miya F; Arai Y; Takahashi H; Shirakihara T; Nagasaki M; Shibuya T; Nakano K; Watanabe-Makino K; Tanaka H; Nakamura H; Kusuda J; Ojima H; Shimada K; Okusaka T; Ueno M; Shigekawa Y; Kawakami Y; Arihiro K; Ohdan H; Gotoh K; Ishikawa O; Ariizumi S; Yamamoto M; Yamada T; Chayama K; Kosuge T; Yamaue H; Kamatani N; Miyano S; Nakagama H; Nakamura Y; Tsunoda T; Shibata T; Nakagawa H
Nat Genet; 2012 May; 44(7):760-4. PubMed ID: 22634756
[TBL] [Abstract][Full Text] [Related]
28. Hepatocellular carcinoma with persistent hepatitis B virus infection shows unusual downregulation of Ras expression and differential response to Ras mediated signaling.
Bose S; Sakhuja P; Bezawada L; Agarwal AK; Kazim SN; Khan LA; Sarin SK; Ramakrishna G
J Gastroenterol Hepatol; 2011 Jan; 26(1):135-44. PubMed ID: 21175807
[TBL] [Abstract][Full Text] [Related]
29. MYH Y165C and G382D mutations in hepatocellular carcinoma and cholangiocarcinoma patients.
Baudhuin LM; Roberts LR; Enders FT; Swanson RL; Mettler TA; Aderca I; Stadheim LM; Highsmith WE
J Cancer Res Clin Oncol; 2006 Mar; 132(3):159-62. PubMed ID: 16292541
[TBL] [Abstract][Full Text] [Related]
30. Copy number aberrations in combined hepatocellular carcinoma and cholangiocarcinoma.
You HL; Weng SW; Li SH; Wei YC; Sheu JJ; Chen CM; Huang WT
Exp Mol Pathol; 2012 Jun; 92(3):281-6. PubMed ID: 22366251
[TBL] [Abstract][Full Text] [Related]
31. Microsatellite alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Koo SH; Ihm CH; Kwon KC; Lee JS; Park JW; Kim JW
Cancer Genet Cytogenet; 2003 Oct; 146(2):139-44. PubMed ID: 14553948
[TBL] [Abstract][Full Text] [Related]
32. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.
Chan-On W; Nairismägi ML; Ong CK; Lim WK; Dima S; Pairojkul C; Lim KH; McPherson JR; Cutcutache I; Heng HL; Ooi L; Chung A; Chow P; Cheow PC; Lee SY; Choo SP; Tan IB; Duda D; Nastase A; Myint SS; Wong BH; Gan A; Rajasegaran V; Ng CC; Nagarajan S; Jusakul A; Zhang S; Vohra P; Yu W; Huang D; Sithithaworn P; Yongvanit P; Wongkham S; Khuntikeo N; Bhudhisawasdi V; Popescu I; Rozen SG; Tan P; Teh BT
Nat Genet; 2013 Dec; 45(12):1474-8. PubMed ID: 24185513
[TBL] [Abstract][Full Text] [Related]
33. Look into hepatic progenitor cell associated trait: Histological heterogeneity of hepatitis B-related combined hepatocellular-cholangiocarcinoma.
Cai X; Xiong J; Hu QG; Zhao QD; Wu D; Tang LG; Wan CD; Wei LX
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):873-879. PubMed ID: 29270746
[TBL] [Abstract][Full Text] [Related]
34. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
35. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
[TBL] [Abstract][Full Text] [Related]
36. Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways.
Kongpetch S; Jusakul A; Ong CK; Lim WK; Rozen SG; Tan P; Teh BT
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):233-44. PubMed ID: 25966424
[TBL] [Abstract][Full Text] [Related]
37. Arid1a mutation suppresses TGF-β signaling and induces cholangiocarcinoma.
Guo B; Friedland SC; Alexander W; Myers JA; Wang W; O'Dell MR; Getman M; Whitney-Miller CL; Agostini-Vulaj D; Huber AR; Mello SS; Vertino PM; Land HK; Steiner LA; Hezel AF
Cell Rep; 2022 Aug; 40(9):111253. PubMed ID: 36044839
[TBL] [Abstract][Full Text] [Related]
38.
Ho DWH; Chan LK; Chiu YT; Xu IMJ; Poon RTP; Cheung TT; Tang CN; Tang VWL; Lo ILO; Lam PWY; Yau DTW; Li MX; Wong CM; Ng IOL
Gut; 2017 Aug; 66(8):1496-1506. PubMed ID: 27974549
[TBL] [Abstract][Full Text] [Related]
39. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
40. Genetics of hepatobiliary carcinogenesis.
Nault JC; Zucman-Rossi J
Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
